Ifosfamide Injection Shortage
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Ifosfamide Injection is currently in shortage, with multiple manufacturers reporting limited availability or backorders due to manufacturing compliance requirements.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on July 3, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Ifosfamide.
What's in Shortage
Ifosfamide Injection (brand names: IFEX, IFOSFAMIDE) is in current shortage. The dosage form is Injection and it belongs to the therapeutic categories of Oncology and Pediatric. The shortage was first posted on 06/12/2026 and last updated on 06/12/2026.
Which Manufacturers Are Affected
- Baxter Healthcare: Currently out of stock (IFEX, Injection, 3 g/60 mL, NDC 0338-3993-01; contact 888-229-0001). Currently out of stock (Ifosfamide, Injection, 3 g/60 mL, NDC 10019-926-02; contact 888-229-0001). Limited availability: Stock currently available until 2nd week of August (Ifosfamide, Injection, 1 g/20 mL, NDC 10019-925-01; contact 888-229-0001; estimated recovery by the end of August). Available (IFEX, Injection, 1 g/20 mL, NDC 0338-3991-01; contact 888-229-0001).
- Hikma Pharmaceuticals USA, Inc.: Temporarily on backorder (Ifosfamide, Injection, 50 mg/1 mL, NDC 0143-9531-01; contact 800-631-2174; additional lots available July 2026). Temporarily on backorder (Ifosfamide, Injection, 50 mg/1 mL, NDC 0143-9530-01; contact 800-631-2174; additional lots June–July 2026).
- Fresenius Kabi USA, LLC: Unavailable (Ifosfamide, Injection, 1 g, NDC 63323-142-10; contact 888-386-1300; next release August 2026).
Why There's a Shortage
The shortage reason is requirements related to complying with good manufacturing practices.
What Patients Should Do
Patients should talk to their pharmacist about current availability, ask about alternatives if appropriate, and contact the manufacturer directly using the provided numbers. Patients should consult their healthcare provider for personalized guidance. Do not make changes to medication without professional medical advice.
Source
FDA Drug Shortage Database
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.